FLT3 and leukemia: These clones carried mutations of TP53, RAS pathway (NRAS, KRAS, BRAF, PTPN11, CBL), IDH1/2, ASXL1 or TET2. The emergence of these mutations, particularly when they occurred in wildtype FLT3 clones, demonstrated FLT3-independent leukaemia cells that were selected under the pressure of FLT3 inhibitors to which they were resistant.